Evidence map›Paper›PMID 42870126›Full record

ArticleVirchows Archiv : an international journal of pathology2026

Expanding the genetic landscape of seromucinous hamartoma: novel HMGA2::PHF14 gene fusion - a case report.

Petr Slavík, Tomáš Vaněček, Petr Šteiner, Michal Michal, Martina Bradová

Abstract read
PubMed Publisher
In one paragraph

Article in Virchows Archiv : an international journal of pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Petr SlavíkDepartment of Pathology, Faculty of Medicine in Plzen, Charles University, University Hospital Plzen, Plzen, Czech Republic.
Tomáš VaněčekBioptic Laboratory, Ltd, Plzen, Czech Republic.
Petr ŠteinerBioptic Laboratory, Ltd, Plzen, Czech Republic.
Michal MichalDepartment of Pathology, Faculty of Medicine in Plzen, Charles University, University Hospital Plzen, Plzen, Czech Republic.
Martina BradováDepartment of Pathology, Faculty of Medicine in Plzen, Charles University, University Hospital Plzen, Plzen, Czech Republic. bradova@biopticka.cz.ORCID http://orcid.org/0000-0002-5829-5572

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Seromucinous hamartomas (SH) are benign polypoid proliferations of small eosinophilic glands arising in the sinonasal tract. Together with respiratory epithelial adenomatoid hamartoma (REAH), they form a morphological continuum, and their hamartomatous designation has been increasingly questioned. Some authors now consider them stationary precancers potentially linked to tumor development through atypical sinonasal glands arising via the SH pathway. The molecular genetic background of SH remains poorly characterized, with no recurrent genetic alterations identified and no unequivocal molecular signature established to date. Here, we present a case of a 68-year-old woman with SH exhibiting a distinctive immunohistochemical staining pattern and a novel HMGA2::PHF14 fusion. This finding raises further questions about the true nature of a subset of SHs and underscores the need for thorough molecular characterization of these rare lesions.

Indexed as

BenignHMGA2:PHF14 fusionNasal cavityOlfactory epithelial hamartomaRespiratory epithelial adenomatoid hamartomaSeromucinous hamartoma

Identifiers

PMID42870126

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.